BloG

Conventional PCR, sequencing, and more: There are several methods for detecting pathogens in a blood sample, such as in cases of sepsis. Regardless of the method used, it is critical to identify the pathogen as quickly as possible. Early identification allows clinicians, in collaboration with infectious desease specialists, to initiate targeted therapy, thereby improving treatment quality, reducing side effects, and increasing chances of survival. Cube Dx's compact sequencing combines two essential features of infectious disease diagnostics in a single workflow: a broad test panel and rapid results. In this interview, Christoph Reschreiter, CEO and co-founder of Cube Dx, discusses the uniqueness of the technology and how it helps laboratories detect positive results in samples within approximately 3 hours...

...want to read more? Click on picture or heading.

September 13th marks World Sepsis Day. Sepsis ranks among the leading global causes of death, claiming more lives than heart attacks, lung, breast, and colon cancer combined. Early detection and prompt treatment with antibiotics tailored to the specific pathogen can be life-saving. However, current detection methods, especially for sepsis, typically require a median of 48 hours, and in some cases, even several days, to yield results. In this interview, Christoph Reschreiter, CEO and one of the founders of Cube Dx, an expert in the field of diagnostics, discusses the critical importance of early sepsis pathogen detection and how Cube Dx's methodology achieves this within just three to four hours from a blood sample...

...want to read more? Click on picture or heading.

Sepsis, also known as blood poisoning, is one of the leading causes of death worldwide. Early detection and rapid identification of the pathogen are critical to initiating effective therapy. Conventional methods involve culturing microorganisms from the patient’s blood, a process that is time-consuming and can take days. Cube Dx has developed a "compact sequencing" method for rapid detection of sepsis pathogens. In April 2023, the company was awarded first place in the "Research & Development in SMEs" category of the Houska Prize by the B&C Private Foundation, receiving a prize of €150,000 for further research...

...want to read more? Click on picture or heading.